Literature DB >> 2244376

Medical management of congestive heart failure.

A E Arai1, B H Greenberg.   

Abstract

The syndrome of congestive heart failure can result from a variety of cardiac disorders of which left ventricular dysfunction is the most common. The clinical presentation is determined by the interaction between cardiac dysfunction and a series of compensatory mechanisms that are activated throughout the body. Therapy for this disorder is best approached through an understanding of this complex relationship and an appreciation for the influence of preload, afterload, and contractility on cardiac performance. Recent important advances in therapy include the use of combined diuretic therapy, a better understanding of the value of the digitalis glycosides, and evidence that angiotensin-converting enzyme (ACE) inhibitors can relieve symptoms and prolong life. More intensive therapy earlier in the course of congestive heart failure appears to have some clinical benefit. The use of ACE inhibitors during this phase may delay progression of the underlying left ventricular dysfunction. Future therapy will be influenced by the results of ongoing trials that are testing both new agents and expanded indications for drugs that are currently available.

Entities:  

Mesh:

Year:  1990        PMID: 2244376      PMCID: PMC1002571     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  57 in total

1.  Plasma norepinephrine in congestive heart failure.

Authors:  J A Thomas; B H Marks
Journal:  Am J Cardiol       Date:  1978-02       Impact factor: 2.778

2.  Rapidly developing tolerance to transdermal nitroglycerin in congestive heart failure.

Authors:  R A Jordan; L Seth; P Casebolt; M J Hayes; M M Wilen; J Franciosa
Journal:  Ann Intern Med       Date:  1986-03       Impact factor: 25.391

3.  The natural history of congestive heart failure: the Framingham study.

Authors:  P A McKee; W P Castelli; P M McNamara; W B Kannel
Journal:  N Engl J Med       Date:  1971-12-23       Impact factor: 91.245

4.  Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure.

Authors:  M Packer; J Meller; R Gorlin; M V Herman
Journal:  Circulation       Date:  1979-03       Impact factor: 29.690

5.  Verapamil-digoxin interaction.

Authors:  H O Klein; R Lang; E Di Segni; E Kaplinsky
Journal:  N Engl J Med       Date:  1980-07-17       Impact factor: 91.245

6.  Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects.

Authors:  R O Bonow; V Dilsizian; D R Rosing; B J Maron; S L Bacharach; M V Green
Journal:  Circulation       Date:  1985-10       Impact factor: 29.690

7.  Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study.

Authors:  J N Cohn; D G Archibald; S Ziesche; J A Franciosa; W E Harston; F E Tristani; W B Dunkman; W Jacobs; G S Francis; K H Flohr
Journal:  N Engl J Med       Date:  1986-06-12       Impact factor: 91.245

8.  Beneficial effects of hydralazine in severe mitral regurgitation.

Authors:  B H Greenberg; B M Massie; B H Brundage; E H Botvinick; W W Parmley; K Chatterjee
Journal:  Circulation       Date:  1978-08       Impact factor: 29.690

9.  Quinidine-digoxin interaction: Pharmacokinetics, underlying mechanism and clinical implications.

Authors:  W Doering
Journal:  N Engl J Med       Date:  1979-08-23       Impact factor: 91.245

10.  Does verapamil improve left ventricular relaxation in patients with myocardial hypertrophy?

Authors:  O M Hess; T Murakami; H P Krayenbuehl
Journal:  Circulation       Date:  1986-09       Impact factor: 29.690

View more
  1 in total

1.  Managing congestive heart failure medically--what have we learned?

Authors:  K Chatterjee
Journal:  West J Med       Date:  1990-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.